Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)
South Korea
· Delayed Price · Currency is KRW 8,050.00
-300.00 (-3.59%)
Apr 2, 2025, 3:30 PM KST
Vaxcell-Bio Therapeutics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Net Income | -10,624 | -10,274 | -6,825 | -4,763 | -3,984 | Upgrade
|
| Depreciation & Amortization | 1,466 | 399.68 | 311.34 | 257.25 | 185.31 | Upgrade
|
| Loss (Gain) From Sale of Assets | 32.73 | - | 0.05 | 0.25 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 182.7 | 126.84 | - | - | - | Upgrade
|
| Stock-Based Compensation | 208.74 | 181.65 | 38.22 | 46.92 | 132.03 | Upgrade
|
| Other Operating Activities | -230.89 | 376.03 | 713.6 | 350.44 | 535.3 | Upgrade
|
| Change in Accounts Receivable | -821.7 | -0.08 | - | - | - | Upgrade
|
| Change in Inventory | -87.47 | -96.74 | - | - | - | Upgrade
|
| Change in Accounts Payable | 226.21 | - | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | -1,051 | -136.3 | -282.79 | -553.84 | -171.64 | Upgrade
|
| Operating Cash Flow | -10,699 | -9,423 | -6,045 | -4,662 | -3,303 | Upgrade
|
| Capital Expenditures | -2,125 | -165.8 | -167.38 | -2,124 | -26.91 | Upgrade
|
| Sale of Property, Plant & Equipment | 127.27 | - | - | - | - | Upgrade
|
| Cash Acquisitions | -4,828 | - | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -1,941 | -32.7 | -122.83 | -104.05 | -5.02 | Upgrade
|
| Investment in Securities | 19,441 | -50,998 | 4,998 | -1,000 | -20,000 | Upgrade
|
| Other Investing Activities | -352.34 | -590.65 | -373.99 | -9 | -17.41 | Upgrade
|
| Investing Cash Flow | 10,322 | -51,787 | 4,333 | -3,237 | -20,049 | Upgrade
|
| Long-Term Debt Repaid | -849.19 | -216.66 | -207.85 | -205.83 | -185.75 | Upgrade
|
| Net Debt Issued (Repaid) | -849.19 | -216.66 | -207.85 | -205.83 | -185.75 | Upgrade
|
| Issuance of Common Stock | - | 71,790 | - | 597.38 | 29,366 | Upgrade
|
| Repurchase of Common Stock | - | -532.7 | - | - | - | Upgrade
|
| Other Financing Activities | 0.34 | -1,174 | - | -86.8 | - | Upgrade
|
| Financing Cash Flow | -848.85 | 69,866 | -207.85 | 304.75 | 29,180 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | -0 | - | - | - | 0 | Upgrade
|
| Net Cash Flow | -1,225 | 8,657 | -1,919 | -7,594 | 5,828 | Upgrade
|
| Free Cash Flow | -12,824 | -9,589 | -6,212 | -6,785 | -3,330 | Upgrade
|
| Free Cash Flow Margin | -675.31% | -69872.25% | - | - | - | Upgrade
|
| Free Cash Flow Per Share | -558.88 | -489.05 | -408.07 | -448.78 | -488.95 | Upgrade
|
| Cash Income Tax Paid | 141.28 | 52.84 | 59.86 | 5.16 | -8.26 | Upgrade
|
| Levered Free Cash Flow | -12,669 | -7,065 | -4,650 | -6,434 | -2,291 | Upgrade
|
| Unlevered Free Cash Flow | -12,529 | -7,037 | -4,640 | -6,417 | -2,270 | Upgrade
|
| Change in Net Working Capital | 621.54 | 228.11 | -433.62 | 803.58 | -104.3 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.